跳至主要内容
临床试验/NCT01873625
NCT01873625已完成2 期

Resurfacing Articular Cartilage With Mesenchymal Stem Cells Transplantation in Patients With Knee Joint Osteoarthritis Affected by Rheumatoid Arthritis: Randomized Triple Blind Clinical Trial Phase II/III (ACRCT)

Royan Institute2 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2009年10月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
60
试验地点
2
主要终点
pain

研究概览

简要总结

Osteoarthritis of the knee is one of the most common causes of disability among elderly. Arthritis rheumatoid is an autoimmune disease which causes multi articular arthritis, such as knee osteoarthritis. As the disease progresses the cartilage become frustrated, surrounding bone react to become thicker and inflammation occurs in subchondral bone seen in T2-weighted MRI as increase in signal density. Patients are treated initially by pain management. In patients who don't response to first line treatment invasive treatment like total knee replacement is done. The investigators designed this clinical study with the aim of evaluating therapeutic effects of intra-articular injection of bone marrow mesenchymal stem cells (BM-MSCs) in 60 patients with knee osteoarthritis.

详细描述

In this study all eligible patients were randomly allocated into two study groups by a permuted block randomization method: group A (control group) received only routine medical therapies and placebo injected into there knees.. Group B received mesenchymal stem cells in addition of routine medical therapy.

Patients were categorized according to the following stimulation protocols:

To assess the outcomes, after mesenchymal stem cells transplantation at months 1,3,6 and 12 we will examine the patients by: WOMAC questioners, DAS28 scoring , radiographies assessments and biochemical analysis with laboratory tests.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
10 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 to 65 years
  • Body mass index (BMI) ≤30 kg/m2
  • The presence of osteoarthritis based on MRI and American Rheumatism Association criteria since 6 months before invitation

排除标准

  • Response to routine treatment at last one year.

研究组 & 干预措施

placebo

Placebo Comparator

Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.

干预措施: placebo (Biological)

mesencymal stem cell

Active Comparator

Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.

干预措施: mesenchymal cell transplantation (Biological)

结局指标

主要结局

pain

时间窗: 1month

Evaluation the pain reduction after mesenchymal stem cell transplantation that measured by VAS scaling.

physical activity

时间窗: 1month

evaluation the improvement of physical activity after mesenchymal stem cell transplantation that measured by WOMAC scoring.

walking distance

时间窗: 1month

Evaluation the walking distance after mesenchymal transplantation.

次要结局

  • Imaging(6months)

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验